Ascletis submits an application to the US FDA for ASC30 39 FDC, a potential first-in-class Oral Small Molecule-Dose combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the treatment of obesity - the company announces.
🇺🇸 USA · Map
Ascletis submits an application to the US FDA for ASC30 39 FDC, a potential first-in-class Oral Small Molecule-Dose combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the treatment of obesity - the company announces.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in